bluebird bio Inc. | Ownership
Companies that own bluebird bio Inc.
Fidelity Management & Research Co.
7,456,990
13.77%
-6,519
0.13%
06/30/2018
Capital Research & Management Co. (Global Investors)
6,139,530
11.34%
16,550
0.19%
06/30/2018
Baillie Gifford & Co.
4,843,399
8.94%
-198,668
0.51%
06/30/2018
The Vanguard Group, Inc.
4,167,348
7.7%
65,002
0.02%
06/30/2018
Wellington Management Co. LLP
2,949,440
5.45%
471,805
0.09%
06/30/2018
T. Rowe Price Associates, Inc.
2,825,093
5.22%
-22,129
0.07%
06/30/2018
Capital Research & Management Co. (World Investors)
2,493,755
4.61%
393,000
0.06%
06/30/2018
BlackRock Fund Advisors
2,481,772
4.58%
-1,008,116
0.02%
06/30/2018
Capital Research & Management Co. (International Investors)
1,129,709
2.09%
112,961
0.2%
06/30/2018
SSgA Funds Management, Inc.
975,963
1.8%
-288,009
0.01%
06/30/2018
| Address |
60 Binney Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.bluebirdbio.com |
| Updated |
07/08/2019 |
| bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy. |
